GT Biopharma Announces IND Clearance From FDA For GTB-5550 In Multiple Myeloma

GT Biopharma, Inc. announced that it has received IND clearance from the FDA for its investigational drug GTB-5550 targeting multiple myeloma, which will proceed under an investigator sponsored trial protocol. The initiation of a Phase 1 trial in multiple myeloma patients is contingent upon the timing and receipt of non-dilutive grant funding. Additionally, the company is actively enrolling patients in a Phase 1 dose escalation trial for GTB-5550 in solid tumors, with results expected in Q4 2026. As of September 15, 2026, GT Biopharma anticipates a cash balance of approximately $11 million, which is expected to sustain operations into Q3 2027.